We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00270881
First Posted: December 29, 2005
Last Update Posted: April 6, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Takehiko Mori, M.D., Ph.D., Keio University
  Purpose
The primary purpose of this study is to evaluate the safety and efficacy of cord blood transplantation for adult patients with hematologic malignancies including refractory acute leukemia. The transplant procedure was determined in detail according to the previously published report showing a high survival, so that the investigators could expect a similar result.

Condition Intervention Phase
Acute Myelogenous Leukemia Acute Lymphoblastic Leukemia Chronic Myelogenous Leukemia Myelodysplastic Syndrome Procedure: Cord blood transplantation Radiation: TBI Drug: cyclophosphamide Drug: cytarabine Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1/2 Study of Cord Blood Transplantation From Unrelated Donor for Adult Patients With Hematologic Malignancies Using Myeloablative Conditioning Regimen

Resource links provided by NLM:


Further study details as provided by Takehiko Mori, M.D., Ph.D., Keio University:

Primary Outcome Measures:
  • Non-relapse mortality at 1 year [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Engraftment [ Time Frame: day 56 ]
  • Disease free survival [ Time Frame: 1 year ]
  • Overall survival [ Time Frame: 1 year ]
  • Incidence of acute and chronic graft-versus-host disease [ Time Frame: day100 and 1 year ]
  • Incidence of infectious complication [ Time Frame: 1year ]
  • Duration of hospitalization [ Time Frame: 1 year ]
  • Immune reconstitution after transplantation [ Time Frame: 1 year ]

Enrollment: 33
Study Start Date: January 2006
Study Completion Date: January 2011
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: Cord blood transplantation
    unrelated cord blood transplantation
    Radiation: TBI
    Total body irradiation (TBI) 12Gy
    Drug: cyclophosphamide
    cyclophosphamide 120mg/kg
    Drug: cytarabine
    cytarabine 3g/m2x4
Detailed Description:
Although cord blood is considered as an alternative donor source for allogeneic hematopoietic stem cell transplantation, its procedure has yet to be standardized. Recently, a single institute result of cord blood transplantation for adult patients with hematologic malignancies have been reported by Takahashi et al (Blood 2004:104;3813-3820), in which the survival was significantly better than that of bone marrow transplantation from unrelated donor. The purpose of this study was to reevaluate the safety and efficacy of cord blood transplantation for adult patients with hematologic malignancies using the same transplant procedures in a multi-institutional setting.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of acute leukemia, chronic myelogenous leukemia, and myelodysplastic syndrome
  • Lack of HLA-identical or 1 locus mismatched related donor
  • Age over 20, and under 55
  • Performance status 0 or 1
  • No moderate or sever organ dysfunction (liver, kidney, heart, lungs)
  • No anti-HLA antibody
  • Informed consent was obtained

Exclusion Criteria:

  • Uncontrollable diabetes
  • Uncontrollable hypertension
  • Active infection
  • TPHA, HBs-Ag, HCV-Ab positive
  • HTLV-I, HIV positive
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00270881


Locations
Japan
Keio University School of Medicine
Tokyo, Japan, 160-8582
Sponsors and Collaborators
Keio University
Investigators
Study Chair: Hisashi Sakamaki, M.D., Ph.D. Tokyo Metropolitan Komagome Hospital
  More Information

Responsible Party: Takehiko Mori, M.D., Ph.D., Dr., Keio University
ClinicalTrials.gov Identifier: NCT00270881     History of Changes
Other Study ID Numbers: KSGCT-CB2005
First Submitted: December 28, 2005
First Posted: December 29, 2005
Last Update Posted: April 6, 2012
Last Verified: April 2012

Keywords provided by Takehiko Mori, M.D., Ph.D., Keio University:
cord blood transplantation
myeloablative regimen
hematologic malignancies

Additional relevant MeSH terms:
Leukemia
Neoplasms
Myelodysplastic Syndromes
Preleukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Myeloproliferative Disorders
Cyclophosphamide
Cytarabine
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antimetabolites, Antineoplastic